JP2008530248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530248A5 JP2008530248A5 JP2007556407A JP2007556407A JP2008530248A5 JP 2008530248 A5 JP2008530248 A5 JP 2008530248A5 JP 2007556407 A JP2007556407 A JP 2007556407A JP 2007556407 A JP2007556407 A JP 2007556407A JP 2008530248 A5 JP2008530248 A5 JP 2008530248A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- taxane
- nanoparticles
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 23
- 239000002105 nanoparticle Substances 0.000 claims 23
- 229940127089 cytotoxic agent Drugs 0.000 claims 22
- 229940123237 Taxane Drugs 0.000 claims 20
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 20
- 102000014914 Carrier Proteins Human genes 0.000 claims 18
- 108010078791 Carrier Proteins Proteins 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- 102000009027 Albumins Human genes 0.000 claims 6
- 108010088751 Albumins Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000002062 proliferating effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 229950007866 tanespimycin Drugs 0.000 claims 4
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical group N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 4
- -1 vinca alkaloid Substances 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 3
- 229940122803 Vinca alkaloid Drugs 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 229940100198 alkylating agent Drugs 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 239000003817 anthracycline antibiotic agent Substances 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 229940100197 antimetabolite Drugs 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 239000003207 proteasome inhibitor Substances 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 101710183280 Topoisomerase Proteins 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229940041033 macrolides Drugs 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
- CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65424505P | 2005-02-18 | 2005-02-18 | |
| US60/654,245 | 2005-02-18 | ||
| PCT/US2006/006167 WO2006089290A1 (en) | 2005-02-18 | 2006-02-21 | Combinations and modes of administration of therapeutic agents and combination therapy |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012156721A Division JP2012193205A (ja) | 2005-02-18 | 2012-07-12 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2013001664A Division JP2013064014A (ja) | 2005-02-18 | 2013-01-09 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2015092577A Division JP6513467B2 (ja) | 2005-02-18 | 2015-04-30 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008530248A JP2008530248A (ja) | 2008-08-07 |
| JP2008530248A5 true JP2008530248A5 (https=) | 2009-04-16 |
| JP5769358B2 JP5769358B2 (ja) | 2015-08-26 |
Family
ID=36593193
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556407A Expired - Lifetime JP5769358B2 (ja) | 2005-02-18 | 2006-02-21 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2012156721A Withdrawn JP2012193205A (ja) | 2005-02-18 | 2012-07-12 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2013001664A Withdrawn JP2013064014A (ja) | 2005-02-18 | 2013-01-09 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2014180852A Expired - Lifetime JP6092824B2 (ja) | 2005-02-18 | 2014-09-05 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2015092577A Expired - Lifetime JP6513467B2 (ja) | 2005-02-18 | 2015-04-30 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2016198882A Expired - Lifetime JP6685875B2 (ja) | 2005-02-18 | 2016-10-07 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2018050735A Pending JP2018090643A (ja) | 2005-02-18 | 2018-03-19 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2019195457A Withdrawn JP2020012005A (ja) | 2005-02-18 | 2019-10-28 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012156721A Withdrawn JP2012193205A (ja) | 2005-02-18 | 2012-07-12 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2013001664A Withdrawn JP2013064014A (ja) | 2005-02-18 | 2013-01-09 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2014180852A Expired - Lifetime JP6092824B2 (ja) | 2005-02-18 | 2014-09-05 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2015092577A Expired - Lifetime JP6513467B2 (ja) | 2005-02-18 | 2015-04-30 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2016198882A Expired - Lifetime JP6685875B2 (ja) | 2005-02-18 | 2016-10-07 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2018050735A Pending JP2018090643A (ja) | 2005-02-18 | 2018-03-19 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2019195457A Withdrawn JP2020012005A (ja) | 2005-02-18 | 2019-10-28 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Country Status (25)
| Country | Link |
|---|---|
| US (11) | US8034375B2 (https=) |
| EP (4) | EP2301531B1 (https=) |
| JP (8) | JP5769358B2 (https=) |
| KR (8) | KR20070114753A (https=) |
| CN (4) | CN105288630A (https=) |
| AT (1) | ATE531365T1 (https=) |
| AU (1) | AU2006213999B2 (https=) |
| BR (1) | BRPI0607809A2 (https=) |
| CA (3) | CA2598239C (https=) |
| CY (4) | CY1112907T1 (https=) |
| DK (3) | DK2301531T3 (https=) |
| ES (3) | ES2802541T3 (https=) |
| HU (2) | HUE038768T2 (https=) |
| IL (4) | IL185288A (https=) |
| LT (2) | LT3248600T (https=) |
| LU (1) | LU92484I2 (https=) |
| MX (3) | MX383644B (https=) |
| NZ (2) | NZ595313A (https=) |
| PL (3) | PL2301531T3 (https=) |
| PT (3) | PT1853250E (https=) |
| RU (2) | RU2452482C2 (https=) |
| SG (1) | SG166775A1 (https=) |
| SI (3) | SI1853250T1 (https=) |
| WO (1) | WO2006089290A1 (https=) |
| ZA (1) | ZA200707491B (https=) |
Families Citing this family (204)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| BRPI9810945B8 (pt) * | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| BRPI0314042B8 (pt) | 2002-09-06 | 2021-05-25 | Calando Pharmaceuticals Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
| CN103405405A (zh) * | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| BRPI0406647A (pt) | 2003-01-06 | 2005-12-06 | Angiochem Inc | Método para transportar um composto através da barreira sanguìnea do cérebro |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI1853250T1 (sl) * | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP1890677A4 (en) * | 2005-06-16 | 2013-01-30 | Myriad Genetics Inc | PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
| JP5436856B2 (ja) | 2005-07-15 | 2014-03-05 | アンジオケム インコーポレーティッド | 薬学的複合体における担体としてのアプロチニンポリペプチドの使用 |
| DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| KR101420445B1 (ko) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| BRPI0622006A2 (pt) * | 2006-08-31 | 2011-12-20 | Abraxis Bioscience Llc | usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| AU2015271950B2 (en) * | 2007-03-07 | 2017-09-28 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| WO2008109163A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| NZ580868A (en) * | 2007-04-10 | 2011-07-29 | Myriad Pharmaceuticals Inc | Dosages and methods for the treatment of cancer |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| AU2008236993A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating brain cancer |
| WO2008124823A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Method of treating melanoma |
| NZ580869A (en) * | 2007-04-10 | 2011-02-25 | Myriad Pharmaceuticals Inc | Methods for treating cancer |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| WO2008140751A1 (en) * | 2007-05-11 | 2008-11-20 | Champions Biotechnology, Inc. | Human leiosarcoma and non small cell lung cancer lung xenograft models |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| JP5579057B2 (ja) * | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| US9545384B2 (en) * | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
| CA2686225A1 (en) * | 2007-06-22 | 2008-12-31 | Scidose Llc | Solubilized formulation of docetaxel without tween 80 |
| EP2217063B1 (en) * | 2007-11-08 | 2014-12-17 | Virginia Tech Intellectual Properties, Inc. | Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents |
| US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
| WO2009078755A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| CA2753844A1 (en) * | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
| MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| TR201905480T4 (tr) | 2008-04-18 | 2019-05-21 | Angiochem Inc | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. |
| EP3782612B1 (en) | 2008-05-15 | 2023-11-08 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| MX339014B (es) * | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| MX2011004019A (es) | 2008-10-15 | 2011-06-24 | Angiochem Inc | Conjugados de etoposido y doxorubicina para entrega de farmacos. |
| BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| NZ593343A (en) * | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| WO2010069074A1 (en) | 2008-12-17 | 2010-06-24 | Universite Du Quebec A Montreal | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| CN102427728A (zh) | 2009-03-13 | 2012-04-25 | 阿布拉科斯生物科学有限公司 | 用硫代秋水仙碱衍生物进行联合治疗 |
| CN103932972A (zh) * | 2009-03-30 | 2014-07-23 | 天蓝制药公司 | 聚合物-药剂缀合物、颗粒、组合物和相关使用方法 |
| WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| WO2010121379A1 (en) | 2009-04-20 | 2010-10-28 | Angiochem Inc | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| CA2763040C (en) * | 2009-06-05 | 2018-05-01 | Joan M. Caron | Methods and compositions for the treatment of cancer |
| AU2010268726A1 (en) | 2009-07-02 | 2012-01-19 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US9340697B2 (en) | 2009-08-14 | 2016-05-17 | Nano-C, Inc. | Solvent-based and water-based carbon nanotube inks with removable additives |
| PL2470173T3 (pl) * | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| KR20120092597A (ko) * | 2009-09-18 | 2012-08-21 | 아브락시스 바이오사이언스, 엘엘씨 | 암 치료에 있어 ｓｐａｒｃ 미세환경 시그니처의 용도 |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| WO2011063356A2 (en) * | 2009-11-22 | 2011-05-26 | Sirnaomics, Inc. | Rare earth-doped up-conversion nanoparticles for therapeutic and diagnostic applications |
| CN102822676B (zh) * | 2010-01-12 | 2015-02-18 | 雀巢产品技术援助有限公司 | 用于预测三阴性乳腺癌对疗法的应答的方法 |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130028727A (ko) * | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| WO2011127405A1 (en) * | 2010-04-08 | 2011-10-13 | Sanford-Burnham Medical Research Institute | Methods and compositions for enhanced delivery of compounds |
| EP2382993A1 (en) | 2010-04-19 | 2011-11-02 | KTB Tumorforschungsgesellschaft mbH | Combination of drugs with protein-binding prodrugs |
| WO2011153009A1 (en) * | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| CA2801190A1 (en) | 2010-06-03 | 2011-12-08 | Abraxis Bioscience, Llc | Use of the sparc microenvironment signature in the treatment of cancer |
| BR112012030909A2 (pt) * | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| WO2011156119A1 (en) * | 2010-06-07 | 2011-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| KR101223484B1 (ko) * | 2010-10-05 | 2013-01-17 | 한국과학기술연구원 | 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체 |
| US8884027B2 (en) | 2010-10-22 | 2014-11-11 | University Of Rochester | Melampomagnolide B derivatives as antileukemic and cytotoxic agents |
| RU2013127625A (ru) * | 2010-11-18 | 2014-12-27 | Зе Дженерал Хоспитал Корпорейшен | Новые композиции и применения антигипертензивных средств для терапии рака |
| AU2011336413B2 (en) * | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| WO2013055874A2 (en) * | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| US9125884B2 (en) * | 2011-11-01 | 2015-09-08 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| GB201121924D0 (en) * | 2011-12-20 | 2012-02-01 | Fahy Gurteen Labs Ltd | Detection of breast cancer |
| EP2630971B8 (en) * | 2012-02-21 | 2017-12-13 | Vergell Medical S.A. | Combinations of albumin-based drug delivery systems |
| HRP20181187T1 (hr) | 2012-04-04 | 2018-09-21 | Halozyme, Inc. | Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor |
| WO2014026143A1 (en) * | 2012-08-09 | 2014-02-13 | Pono Corporation | Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof |
| IN2015KN00449A (https=) * | 2012-09-04 | 2015-07-17 | Glaxosmithkline Llc | |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| BR112015010501A2 (pt) | 2012-11-12 | 2017-07-11 | Ignyta Inc | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada |
| WO2014078522A1 (en) | 2012-11-14 | 2014-05-22 | Ohio State Innovation Foundation | Materials and methods useful for treating glioblastoma |
| CN104955801B (zh) | 2012-11-30 | 2017-10-31 | 诺沃梅迪科斯有限公司 | 取代的二芳基磺酰胺及其用途 |
| MX2015007185A (es) * | 2012-12-04 | 2017-09-05 | Eisai R&D Man Co Ltd | Uso de eribulina en el tratamiento de cancer de pecho. |
| CN104688740A (zh) * | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9962452B2 (en) | 2013-02-04 | 2018-05-08 | Zhuhai Beihai Biotech Co., Ltd. | Soluble complexes of drug analogs and albumin |
| EP2953622B1 (en) * | 2013-02-11 | 2021-03-24 | Abraxis BioScience, LLC | Methods of treating melanoma |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| CN105209035A (zh) | 2013-03-13 | 2015-12-30 | 阿布拉科斯生物科学有限公司 | 治疗儿童实体瘤的方法 |
| WO2014160130A1 (en) | 2013-03-13 | 2014-10-02 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| WO2014165842A2 (en) * | 2013-04-05 | 2014-10-09 | Igdrasol | Nanoparticle formulations in biomarker detection |
| KR101329646B1 (ko) * | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
| WO2015038832A1 (en) | 2013-09-11 | 2015-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies |
| WO2015042234A1 (en) * | 2013-09-20 | 2015-03-26 | Igdrasol | Conditionally stable micelle compositions for cancer treatment including ovarian cancer |
| WO2015048467A1 (en) * | 2013-09-27 | 2015-04-02 | Cerulean Pharma Inc. | Treatment of cancer |
| EP3060143B1 (en) * | 2013-10-25 | 2021-01-06 | Mercator Medsystems, Inc. | Maintenance of bronchial patency by local delivery of cytotoxic, cytostatic, or anti-neoplastic agent |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| IL311202A (en) * | 2013-11-15 | 2024-05-01 | Oncoceutics Inc | 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-A] pyrido[3,4-E] pyrimidine-5(1H)one, its salts and methods Use |
| FI20130341A7 (fi) | 2013-11-19 | 2015-05-20 | Oy Safemed Ltd | Huonosti vesiliukoisten lääkeaineiden kuljetus metalli-ioneilla tasapainotetun alfafetoproteiinin mukana |
| SI3076969T1 (sl) * | 2013-12-06 | 2021-12-31 | Novartis Ag | Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze |
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| US20160250351A1 (en) | 2014-06-13 | 2016-09-01 | Mayo Foundation For Medical Education And Research | Treating Lymphomas |
| EP3834889A1 (en) | 2014-06-16 | 2021-06-16 | Mayo Foundation for Medical Education and Research | Treating myelomas |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| US9937259B2 (en) | 2014-06-27 | 2018-04-10 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivatives and non-covalent complexes with albumin |
| CN104434808A (zh) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗性纳米粒子及其制备方法 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US10231958B2 (en) * | 2014-10-24 | 2019-03-19 | The Board Of Regents Of The University Of Texas System | Methods and compositions for enhancing chemotherapy |
| WO2016065139A1 (en) | 2014-10-24 | 2016-04-28 | Fl Therapeutics Llc | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin |
| WO2016123571A1 (en) | 2015-01-30 | 2016-08-04 | Oncoceutics Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| WO2016172515A1 (en) | 2015-04-23 | 2016-10-27 | Sanford Burnham Prebys Medical Discovery Institute | Targeted delivery system and methods of use therefor |
| DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11585805B2 (en) | 2016-02-19 | 2023-02-21 | Nantcell, Inc. | Methods of immunogenic modulation |
| US11305020B2 (en) | 2016-03-21 | 2022-04-19 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| JP2019513021A (ja) | 2016-03-24 | 2019-05-23 | ナントセル，インコーポレイテッド | ネオエピトープ提示のための配列の配置および配列 |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| KR102383824B1 (ko) | 2016-06-02 | 2022-04-06 | 이노파막스, 인크. | 암 치료법을 위한 메트로놈 경구 젬시타빈 |
| WO2018005973A1 (en) | 2016-06-30 | 2018-01-04 | Nant Holdings Ip, Llc | Nant cancer vaccine |
| EP3493855A4 (en) | 2016-08-02 | 2020-04-01 | ISI Life Sciences, Inc. | COMPOSITIONS AND METHOD FOR DETECTING CANCER CELLS IN A TISSUE SAMPLE |
| AU2017307618A1 (en) | 2016-08-05 | 2019-02-21 | Mayo Foundation For Medical Education And Research | Modified antibody-albumin nanoparticle complexes for cancer treatment |
| CN107714652B (zh) * | 2016-08-12 | 2021-03-02 | 四川科伦药物研究院有限公司 | 替西罗莫司白蛋白纳米组合物及其冻干制剂、制法和用途 |
| EP3508205B1 (en) | 2016-08-31 | 2022-05-18 | FUJIFILM Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
| CN109890419A (zh) | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
| CA3035377A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Nanoparticle compositions for targeting t-cell cancers |
| EP3509643A1 (en) * | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| WO2018048816A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| AU2017327392B9 (en) * | 2016-09-13 | 2023-10-12 | Tiziana Life Sciences Plc | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| AU2017361541A1 (en) | 2016-11-21 | 2019-07-11 | Bexion Pharmaceuticals, Inc. | A combination therapy including SapC-DOPS for the treatment of pancreatic cancer |
| AU2017362730B2 (en) | 2016-11-21 | 2021-04-08 | Nant Holdings Ip, Llc | Fractal combination therapy |
| RU2764630C2 (ru) * | 2016-12-21 | 2022-01-19 | Лиминал Байосайенсиз Лимитед | Способы и композиции для предотвращения или минимизации эпителиально-мезенхимального перехода |
| US11229668B2 (en) | 2017-02-07 | 2022-01-25 | Nantcell, Inc. | Maximizing T-cell memory and compositions and methods therefor |
| US20180235936A1 (en) * | 2017-02-17 | 2018-08-23 | University Of Notre Dame Du Lac | Cancer treatment methods |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| IL314202B1 (en) | 2017-04-24 | 2026-04-01 | Nantcell Inc | Neoepitope vectors and methods for them |
| US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
| EP3654976A1 (en) | 2017-07-21 | 2020-05-27 | Varian Medical Systems, Inc. | Methods of use of ultra-high dose rate radiation and therapeutic agents |
| RU2020111019A (ru) * | 2017-08-18 | 2021-09-20 | Трагара Фармасьютикалз, Инк. | Полиморфная форма tg02 |
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| RU2020118594A (ru) | 2017-11-06 | 2021-12-09 | Рапт Терапьютикс, Инк. | Противораковые агенты |
| WO2019143606A1 (en) | 2018-01-17 | 2019-07-25 | Nantbio, Inc. | Enhanced immunogenicity for gpi-anchored antigens |
| FI3743091T3 (fi) | 2018-01-26 | 2025-01-03 | Univ California | Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita |
| KR20250002710A (ko) | 2018-03-01 | 2025-01-07 | 아스트라제네카 에이비이 | (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물 |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| AU2019247655A1 (en) | 2018-04-03 | 2020-10-01 | Vaxess Technologies, Inc. | Microneedle comprising silk fibroin applied to a dissolvable base |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
| CN112423737A (zh) | 2018-05-22 | 2021-02-26 | 阿布拉科斯生物科学有限公司 | 用于治疗肺高压的方法和组合物 |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| WO2020064017A1 (zh) * | 2018-09-30 | 2020-04-02 | 百药智达（北京）纳米生物技术有限公司 | 核酸纳米载体药物、其制备方法、药物组合物及其应用 |
| US20220047617A1 (en) * | 2018-10-16 | 2022-02-17 | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. | Nucleic acid nanocarrier drug, preparation method, pharmaceutical composition and use thereof |
| WO2020112868A1 (en) * | 2018-11-30 | 2020-06-04 | Aileron Therapeutics, Inc. | Combination therapy of peptidomimetic macrocycles |
| RU2706347C1 (ru) * | 2019-07-24 | 2019-11-18 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России | Способ лечения операбельной аденокарциномы головки поджелудочной железы |
| JP7832108B2 (ja) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
| CN114949200B (zh) * | 2021-02-20 | 2025-08-19 | 北京大学人民医院 | 全反式维a酸联合低剂量利妥昔单抗在制备治疗激素耐药或复发itp的药物中的应用 |
| WO2022232420A1 (en) * | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
| US20250177352A1 (en) | 2022-03-14 | 2025-06-05 | Laekna Limited | Combination treatment for cancer |
| CA3260638A1 (en) | 2022-06-24 | 2023-12-28 | Terrestrial Bio, Inc. | MEDICATION TAMP APPLICATOR |
| EP4577212A1 (en) * | 2022-08-26 | 2025-07-02 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| EP4704842A1 (en) | 2023-04-30 | 2026-03-11 | Aadi Bioscience, Inc. | Treatments comprising an mtor inhibitor nanoparticle composition |
| EP4719365A1 (en) | 2023-05-24 | 2026-04-08 | Aadi Bioscience, Inc. | Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma |
| WO2024263835A1 (en) | 2023-06-23 | 2024-12-26 | Vaxess Technologies, Inc. | Applicator for medicament patch |
| WO2025034870A1 (en) | 2023-08-08 | 2025-02-13 | Aadi Bioscience, Inc. | Combination of nab-sirolimus and an estrogen suppresor for use in the treatment of hormone-dependent cancers |
| WO2025049962A1 (en) | 2023-08-31 | 2025-03-06 | Aadi Bioscience, Inc. | Combination cancer treatments with a composition comprising an mtor pathway inhibitor |
| WO2025129108A1 (en) | 2023-12-14 | 2025-06-19 | Aadi Bioscience, Inc. | Methods of treating a cancer in an individual |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| FR2660556B1 (fr) | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | Microspheres, leur procede de preparation et leur utilisation. |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| EP0531472B1 (en) | 1991-03-06 | 2003-08-13 | MERCK PATENT GmbH | Humanized monoclonal antibodies |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US20070117862A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030073642A1 (en) | 1993-02-22 | 2003-04-17 | American Bioscience, Inc. | Methods and formulations for delivery of pharmacologically active agents |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US20030133955A1 (en) | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| BR9405798A (pt) * | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| EP1155689B1 (en) | 1993-07-19 | 2006-09-20 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic stents and methods of their preparation |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| WO1995019171A1 (en) | 1994-01-14 | 1995-07-20 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
| AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
| US5744460A (en) | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| DE69735057T2 (de) | 1996-03-12 | 2006-08-31 | PG-TXL Co., L.P., Houston | Wasserlösliche paclitaxel-prodrogen |
| US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| EP1208847B8 (en) | 1996-07-30 | 2007-02-14 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| BRPI9810945B8 (pt) * | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US6258084B1 (en) | 1997-09-11 | 2001-07-10 | Vnus Medical Technologies, Inc. | Method for applying energy to biological tissue including the use of tumescent tissue compression |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| HUP0102048A3 (en) | 1998-04-16 | 2002-12-28 | Eurovita As | Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga and their use |
| WO2000006152A1 (en) * | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| US6682758B1 (en) | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6537585B1 (en) * | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| CA2684454A1 (en) | 1999-05-21 | 2000-11-18 | American Bioscience, Llc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| MXPA01011981A (es) | 1999-05-24 | 2003-09-04 | Sonus Pharma Inc | Vehiculo de emulsion para farmacos poco solubles. |
| JP2003527337A (ja) | 1999-11-12 | 2003-09-16 | エントレメッド インコーポレイテッド | 抗血管新生スケジュールに基づく治療薬の投与方法 |
| US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| IT1318401B1 (it) * | 2000-03-17 | 2003-08-25 | Indena Spa | Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono. |
| AU2001253334A1 (en) | 2000-04-10 | 2001-10-23 | Teva Pharmaceutical Industries Ltd. | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| PL204958B1 (pl) | 2000-06-30 | 2010-02-26 | Glaxo Group Ltd | Ditosylany związków chinazolinowych, środek farmaceutyczny i zastosowanie tych związków |
| AU2001292548B2 (en) | 2000-07-28 | 2005-06-16 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| HUP0302599A3 (en) | 2000-09-22 | 2005-05-30 | Bristol Myers Squibb Co | Method for reducing toxicity of combined chemotherapic compositions |
| DE60203260T2 (de) | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| EP1351677A4 (en) | 2001-01-19 | 2009-08-19 | Bionumerik Pharmaceuticals Inc | CANCER TREATMENT METHOD |
| US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| GB0103668D0 (en) | 2001-02-15 | 2001-03-28 | Biointeractions Ltd | Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| EE200300429A (et) | 2001-03-06 | 2003-12-15 | Bristol-Myers Squibb Company | Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks |
| WO2002069949A2 (en) | 2001-03-06 | 2002-09-12 | Prendergast Patrick T | Combination therapy for reduction of toxycity of chemotherapeutic agents |
| US6752922B2 (en) | 2001-04-06 | 2004-06-22 | Fluidigm Corporation | Microfluidic chromatography |
| US7638161B2 (en) | 2001-07-20 | 2009-12-29 | Applied Materials, Inc. | Method and apparatus for controlling dopant concentration during BPSG film deposition to reduce nitride consumption |
| US6872715B2 (en) | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| US7056338B2 (en) | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
| US20040033271A1 (en) | 2001-12-03 | 2004-02-19 | Seth Lederman | Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| US20040126400A1 (en) | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
| US7794743B2 (en) | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
| WO2004006859A2 (en) | 2002-07-16 | 2004-01-22 | Sonus Pharmaceuticals, Inc. | Platinum compound |
| CA2495962A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| US20050158375A1 (en) * | 2002-11-15 | 2005-07-21 | Toshikiro Kimura | Pharmaceutical composition containing liposomes for treating cancer |
| US20050095267A1 (en) | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
| PT1585548T (pt) * | 2002-12-09 | 2018-10-17 | Abraxis Bioscience Llc | Composições e métodos de administração de agentes farmacológicos |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| MXPA05007382A (es) | 2003-01-10 | 2005-11-23 | Threshold Pharmaceuticals Inc | Tratamiento de cancer con 2-desoxiglucosa. |
| BRPI0408891A (pt) | 2003-03-28 | 2006-04-11 | Kosan Biosciences Inc | dispositivos, métodos, e composições para prevenir restenose |
| EP1643971A2 (en) | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| US20050026893A1 (en) | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| BRPI0414698A (pt) | 2003-09-23 | 2006-11-28 | Novartis Ag | combinação de um inibidor receptor de vegf com um agente quimioterapêutico |
| PL2286794T3 (pl) | 2003-10-15 | 2016-10-31 | Zastosowanie kationowych liposomów zawierających paklitaksel | |
| US20080045559A1 (en) | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| BRPI0415858A (pt) | 2003-10-29 | 2007-01-09 | Sonus Pharma Inc | compostos de medicamentos terapêuticos modificados por tocoferol |
| US20050203174A1 (en) | 2004-03-09 | 2005-09-15 | Kosan Biosciences, Inc. | Combination therapies using leptomycin B |
| WO2005090372A2 (en) | 2004-03-15 | 2005-09-29 | Sonus Pharmaceuticals, Inc. | Platinum carboxylate anticancer compounds |
| WO2006001911A2 (en) | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor beta chain and methods of use |
| US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| EP3327031A1 (en) | 2004-05-14 | 2018-05-30 | Abraxis BioScience, LLC | Disease site-delivering pharmaceutical compositions comprising paclitaxel |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| EP1755608A1 (en) * | 2004-06-03 | 2007-02-28 | F.Hoffmann-La Roche Ag | Treatment with gemcitabine and an egfr-inhibitor |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US7332568B2 (en) | 2005-02-18 | 2008-02-19 | Abraxis Bioscience, Inc. | Q3 SPARC deletion mutant and uses thereof |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| JP5700909B2 (ja) | 2005-05-04 | 2015-04-15 | メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ | パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法 |
| US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| KR101420445B1 (ko) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2007059116A2 (en) | 2005-11-14 | 2007-05-24 | Abraxis Bioscience, Inc. | Geldanamycin derivatives and pharmaceutical compositions thereof |
| MX2008011978A (es) | 2006-03-22 | 2009-04-22 | Medigene Ag | Tratamiento del cancer de seno negativo al triple receptor. |
| US9037257B2 (en) * | 2006-04-07 | 2015-05-19 | Medtronic, Inc. | Resonance tuning module for implantable devices and leads |
| SG136814A1 (en) | 2006-04-12 | 2007-11-29 | Tencube Pte Ltd | System for tracking mobile equipment and associated mobile subscribersæ identity |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| WO2008109163A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| US20090018078A1 (en) | 2007-07-09 | 2009-01-15 | Vinod Labhasetwar | Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same |
| MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| CN102427728A (zh) | 2009-03-13 | 2012-04-25 | 阿布拉科斯生物科学有限公司 | 用硫代秋水仙碱衍生物进行联合治疗 |
| EP2416650B1 (en) | 2009-04-10 | 2020-02-26 | Abraxis BioScience, LLC | Nanoparticle formulations and uses therof |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| PL2470173T3 (pl) | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| EP3085387A1 (en) | 2010-04-26 | 2016-10-26 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
| WO2011153009A1 (en) | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| WO2011156119A1 (en) | 2010-06-07 | 2011-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
-
2006
- 2006-02-21 SI SI200631217T patent/SI1853250T1/sl unknown
- 2006-02-21 AT AT06735710T patent/ATE531365T1/de active
- 2006-02-21 NZ NZ595313A patent/NZ595313A/xx not_active IP Right Cessation
- 2006-02-21 KR KR1020077021327A patent/KR20070114753A/ko not_active Ceased
- 2006-02-21 NZ NZ560879A patent/NZ560879A/en not_active IP Right Cessation
- 2006-02-21 KR KR1020137034986A patent/KR20140016402A/ko not_active Ceased
- 2006-02-21 ES ES17165979T patent/ES2802541T3/es not_active Expired - Lifetime
- 2006-02-21 EP EP10011106.1A patent/EP2301531B1/en not_active Expired - Lifetime
- 2006-02-21 LT LTEP17165979.0T patent/LT3248600T/lt unknown
- 2006-02-21 PT PT06735710T patent/PT1853250E/pt unknown
- 2006-02-21 CN CN201510411744.7A patent/CN105288630A/zh active Pending
- 2006-02-21 CA CA2598239A patent/CA2598239C/en not_active Expired - Lifetime
- 2006-02-21 KR KR1020187031184A patent/KR101976003B1/ko not_active Expired - Lifetime
- 2006-02-21 CA CA2902071A patent/CA2902071C/en not_active Expired - Lifetime
- 2006-02-21 RU RU2007134571/15A patent/RU2452482C2/ru active
- 2006-02-21 SI SI200632272T patent/SI2301531T1/sl unknown
- 2006-02-21 CN CN2013102337091A patent/CN103285395A/zh active Pending
- 2006-02-21 PT PT100111061T patent/PT2301531T/pt unknown
- 2006-02-21 US US11/359,286 patent/US8034375B2/en active Active
- 2006-02-21 EP EP17165979.0A patent/EP3248600B8/en not_active Revoked
- 2006-02-21 KR KR1020177021183A patent/KR101914254B1/ko not_active Expired - Lifetime
- 2006-02-21 ES ES10011106.1T patent/ES2678448T3/es not_active Expired - Lifetime
- 2006-02-21 WO PCT/US2006/006167 patent/WO2006089290A1/en not_active Ceased
- 2006-02-21 JP JP2007556407A patent/JP5769358B2/ja not_active Expired - Lifetime
- 2006-02-21 SG SG201007821-0A patent/SG166775A1/en unknown
- 2006-02-21 KR KR1020157009103A patent/KR101625347B1/ko not_active Expired - Lifetime
- 2006-02-21 HU HUE10011106A patent/HUE038768T2/hu unknown
- 2006-02-21 MX MX2015016754A patent/MX383644B/es unknown
- 2006-02-21 KR KR1020167013205A patent/KR101764375B1/ko not_active Expired - Lifetime
- 2006-02-21 CN CN2006800116779A patent/CN101160123B/zh not_active Expired - Lifetime
- 2006-02-21 DK DK10011106.1T patent/DK2301531T3/en active
- 2006-02-21 MX MX2007009960A patent/MX2007009960A/es active IP Right Grant
- 2006-02-21 SI SI200632377T patent/SI3248600T1/sl unknown
- 2006-02-21 ES ES06735710T patent/ES2375828T3/es not_active Expired - Lifetime
- 2006-02-21 AU AU2006213999A patent/AU2006213999B2/en not_active Expired
- 2006-02-21 BR BRPI0607809-5A patent/BRPI0607809A2/pt not_active Application Discontinuation
- 2006-02-21 HU HUE17165979A patent/HUE049789T2/hu unknown
- 2006-02-21 ZA ZA200707491A patent/ZA200707491B/xx unknown
- 2006-02-21 CN CN2013100757784A patent/CN103169729A/zh active Pending
- 2006-02-21 EP EP06735710A patent/EP1853250B1/en not_active Revoked
- 2006-02-21 DK DK06735710.3T patent/DK1853250T3/da active
- 2006-02-21 DK DK17165979.0T patent/DK3248600T3/da active
- 2006-02-21 KR KR1020207009782A patent/KR20200038337A/ko not_active Ceased
- 2006-02-21 LT LTEP10011106.1T patent/LT2301531T/lt unknown
- 2006-02-21 CA CA3054535A patent/CA3054535A1/en not_active Abandoned
- 2006-02-21 PL PL10011106T patent/PL2301531T3/pl unknown
- 2006-02-21 PL PL17165979T patent/PL3248600T3/pl unknown
- 2006-02-21 MX MX2011009748A patent/MX339142B/es unknown
- 2006-02-21 PL PL06735710T patent/PL1853250T3/pl unknown
- 2006-02-21 EP EP20154548.0A patent/EP3698783A1/en not_active Withdrawn
- 2006-02-21 KR KR1020197012570A patent/KR20190062506A/ko not_active Ceased
- 2006-02-21 PT PT171659790T patent/PT3248600T/pt unknown
- 2006-10-06 US US11/544,242 patent/US8257733B2/en not_active Expired - Lifetime
-
2007
- 2007-07-20 US US11/880,314 patent/US7780984B2/en not_active Expired - Lifetime
- 2007-08-15 IL IL185288A patent/IL185288A/en active IP Right Grant
-
2008
- 2008-12-12 US US12/334,115 patent/US7758891B2/en not_active Expired - Lifetime
-
2011
- 2011-09-08 US US13/228,323 patent/US8268348B2/en not_active Expired - Lifetime
-
2012
- 2012-01-05 CY CY20121100013T patent/CY1112907T1/el unknown
- 2012-02-22 RU RU2012106620A patent/RU2632103C2/ru active
- 2012-06-21 IL IL220547A patent/IL220547A0/en unknown
- 2012-07-12 JP JP2012156721A patent/JP2012193205A/ja not_active Withdrawn
- 2012-08-01 US US13/564,633 patent/US20130195922A1/en not_active Abandoned
- 2012-08-14 US US13/585,696 patent/US9101543B2/en not_active Expired - Lifetime
-
2013
- 2013-01-09 JP JP2013001664A patent/JP2013064014A/ja not_active Withdrawn
- 2013-02-25 US US13/776,481 patent/US20140023717A1/en not_active Abandoned
- 2013-02-25 US US13/776,484 patent/US20140017315A1/en not_active Abandoned
-
2014
- 2014-06-18 LU LU92484C patent/LU92484I2/xx unknown
- 2014-06-19 CY CY2014023C patent/CY2014023I1/el unknown
- 2014-08-25 US US14/468,127 patent/US20150079177A1/en not_active Abandoned
- 2014-09-05 JP JP2014180852A patent/JP6092824B2/ja not_active Expired - Lifetime
-
2015
- 2015-04-30 JP JP2015092577A patent/JP6513467B2/ja not_active Expired - Lifetime
-
2016
- 2016-10-07 JP JP2016198882A patent/JP6685875B2/ja not_active Expired - Lifetime
-
2017
- 2017-06-06 IL IL252715A patent/IL252715A0/en unknown
- 2017-10-18 US US15/787,586 patent/US20180169017A1/en not_active Abandoned
-
2018
- 2018-03-19 JP JP2018050735A patent/JP2018090643A/ja active Pending
- 2018-07-20 CY CY20181100760T patent/CY1120445T1/el unknown
-
2019
- 2019-10-28 JP JP2019195457A patent/JP2020012005A/ja not_active Withdrawn
-
2020
- 2020-04-02 IL IL273765A patent/IL273765A/en unknown
- 2020-06-25 CY CY20201100579T patent/CY1123110T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008530248A5 (https=) | ||
| Ventola | Progress in nanomedicine: approved and investigational nanodrugs | |
| RU2743643C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| US11648211B2 (en) | Nanoencapsulated combination drug formulations | |
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| RU2007134571A (ru) | Комбинация и способы введения терапевтических средств и комбинированной терапии | |
| JP2010520289A5 (https=) | ||
| JP2021510725A5 (https=) | ||
| JP2020524698A5 (https=) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| PT1827437E (pt) | Combinação de agentes terapêuticos para o tratamento do cancro | |
| JP2003533485A5 (https=) | ||
| JP2009515901A5 (https=) | ||
| Hernandez-Aya et al. | Chemotherapy principles of managing stage IV breast cancer in the United States | |
| TW200404532A (en) | Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| WO2017184086A1 (en) | Method of treating liver cancer | |
| Chougule et al. | Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer | |
| CN103370066A (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| JP2010504307A5 (https=) | ||
| CN1615136A (zh) | 包含埃坡霉素和抗代谢物的组合 | |
| JP2005511663A5 (https=) | ||
| JP2005511663A (ja) | 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 | |
| CN103442708B (zh) | 治疗性处理 |